Lesson plan
IPLA
iPLA, also known as N-isopropyllysergamide, as well as lysergic acid isopropylamide (LAiP), is a serotonin receptor modulator and possible serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethyl groups have been replaced with an N-isopropyl group. In an early study, iPLA showed about 22.2% of the antiserotonergic activity of LSD in the isolated rat uterus. The drug is known to bind with high affinity (K i ) to the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 1A receptors. It is a potent agonist of the serotonin 5-HT 2A receptor. iPLA fully substituted for LSD in rodent drug discrimination tests with a potency of about half that of LSD itself, findings which suggest that iPLA may have psychedelic effects in humans. iPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada as of 2025.
Article summary
iPLA, also known as N-isopropyllysergamide, as well as lysergic acid isopropylamide (LAiP), is a serotonin receptor modulator and possible serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethyl groups have been replaced with an N-isopropyl group. In an early study, iPLA showed about 22.2% of the antiserotonergic activity of LSD in the isolated rat uterus. The drug is known to bind with high affinity (K i ) to the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 1A receptors. It is a potent agonist of the serotonin 5-HT 2A receptor. iPLA fully substituted for LSD in rodent drug discrimination tests with a potency of about half that of LSD itself, findings which suggest that iPLA may have psychedelic effects in humans. iPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada as of 2025.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.